The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent

References

• Schmoll HJ, Stein A. Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection. Nat Rev Clin Oncol 2014; 11:79-80. PMID:24445520.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Rosch T, Bretthauer M. Colorectal cancer screening–optimizing current strategies and new directions. Nat Rev Clin Oncol 2013; 10:130-42. PMID:23381005.
   PubMed Web of Science ®Google Scholar
• Brouquet A, Nordlinger B. Metastatic colorectal cancer outcome and fatty liver disease. Nat Rev Gastroenterol Hepatol 2013; 10:266-7. PMID:23567218.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29. PMID:24399786.
   PubMed Web of Science ®Google Scholar
• Ekstrand AI, Jonsson M, Lindblom A, Borg A, Nilbert M. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer 2010; 9:125-9. PMID:19731079.
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, et al. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol 2009; 16:2617-28. PMID:19517193.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22. PMID:17613433.
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6:729-34. PMID:16915295.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93. PMID:22500797.
   PubMed Web of Science ®Google Scholar
• Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett 2013; 340:1-8. PMID:23792225.
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia C, Ibrahim YH, Serra V, Calvo MT, Guzman M, Grueso J, et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 2012; 18:2603-12. PMID:22407832.
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010; 20:4308-12. PMID:20561789.
   PubMed Web of Science ®Google Scholar
• Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 2011; 15:63-74. PMID:21110697.
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065-74. PMID:18725988.
   PubMed Web of Science ®Google Scholar
• Ma Y, Machesky LM. Fascin1 in carcinomas: Its regulation and prognostic value. Int J Cancer 2014. PMID:25302416.
   PubMedGoogle Scholar
• Chen MB, Wei MX, Han JY, Wu XY, Li C, Wang J, et al. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer. Cell Signal 2014; 26:102-9. PMID:23899558.
   PubMed Web of Science ®Google Scholar
• Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y, et al. MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and inhibits migration and invasion of colorectal cancer cells. Dig Dis Sci 2010; 55:2365-72. PMID:19830559.
   PubMed Web of Science ®Google Scholar
• Fabre M, Garcia de Herreros A. Phorbol ester-induced scattering of HT-29 human intestinal cancer cells is associated with down-modulation of E-cadherin. J Cell Sci 1993; 106 (Pt 2):513-21. PMID:8282758.
   PubMed Web of Science ®Google Scholar
• Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000; 275:36803-10. PMID:10969078.
   PubMed Web of Science ®Google Scholar
• Chung KY, Saltz LB. Adjuvant therapy of colon cancer: current status and future directions. Cancer J 2007; 13:192-7. PMID:17620769.
   PubMed Web of Science ®Google Scholar
• Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25:6436-46. PMID:17041628.
   PubMed Web of Science ®Google Scholar
• Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011; 10:395-403. PMID:21216931.
   PubMed Web of Science ®Google Scholar
• Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J Mol Biol 1993; 229:105-24. PMID:7678431.
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8. PMID:16452206.
   PubMed Web of Science ®Google Scholar
• Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2:135-64. PMID:21411864.
   PubMed Web of Science ®Google Scholar
• Li Q, Song XM, Ji YY, Jiang H, Xu LG. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem Biophys Res Commun 2013; 440:701-6. PMID:24103749.
   PubMed Web of Science ®Google Scholar
• Rhoads JM, Niu X, Odle J, Graves LM. Role of mTOR signaling in intestinal cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 291:G510-7. PMID:16710051.
   PubMed Web of Science ®Google Scholar
• Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98:2277-83. PMID:8941644.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao GF, Xue J, Wan J, Wan Y, Jiang Q, et al. Tumor necrosis factor-alpha (TNF-alpha)-mediated in vitro human retinal pigment epithelial (RPE) cell migration mainly requires Akt/mTOR complex 1 (mTORC1), but not mTOR complex 2 (mTORC2) signaling. Eur J Cell Biol 2012; 91:728-37. PMID:22595285.
   PubMed Web of Science ®Google Scholar
• Berven LA, Willard FS, Crouch MF. Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 2004; 296:183-95. PMID:15149849.
   PubMed Web of Science ®Google Scholar
• Bu X, Le C, Jia F, Guo X, Zhang L, Zhang B, et al. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol Ther 2008; 7:392-6. PMID:18075305.
   PubMed Web of Science ®Google Scholar
• Lee KH, Hur HS, Im SA, Lee J, Kim HP, Yoon YK, et al. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett 2010; 299:22-8. PMID:20727673.
   PubMed Web of Science ®Google Scholar
• Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003; 14:931-7. PMID:12796032.
   PubMed Web of Science ®Google Scholar